Aclaris Therapeutics Inc., of Malvern, Pa., said it started a phase II, open-label trial of ATI-50002, a topical JAK1/3 inhibitor, for the potential treatment of nonsegmental vitiligo of the face. The trial will evaluate the safety, tolerability and preliminary efficacy of ATI-50002 applied twice daily in 24 adult subjects.